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Abstract: Critical patients with COVID-19 are thought to be at high risk of developing 
chronic pain. However, the exact nature and mechanisms of COVID-19-related chronic pain 
remain largely unknown. Here, we describe clinical features, treatments and outcome of 
herpes zoster as well as postherpetic neuralgia in a 70-year-old woman with critical COVID- 
19. The patient had a history of type 2 diabetes and myasthenia gravis. She developed herpes 
zoster in the right 10 to 12 lumbar dermatomes in the recovery period of COVID-19. 
Intravenous (250 mg 3 times a day) and then oral (400 mg 5 times a day) acyclovir was 
used for antiviral therapy. Pregabalin (75 mg orally twice a day) and ibuprofen was used for 
analgesia. Her skin lesions resolved 21 days after the onset of rash. However, she continued 
to have persistent pain in the same dermatomal distribution. After the dosage of pregabalin 
was increased to 150 mg orally twice a day, her pain was partially relieved. During the 
telephone follow-up 4 months after herpes zoster eruption, the patient still complained 
intermittent pain in the right 10 to 12 lumbar dermatomes. Our case draws attention to 
postherpetic neuralgia in COVID-19 patients and provides a targeted suggestion for this kind 
of patients. 
Keywords: SARS-CoV-2, COVID-19, herpes zoster, postherpetic neuralgia, elderly patient
Introduction
Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the 
outbreak of coronavirus disease 2019 (COVID-19) has spread quickly across the 
world. As of July 27, 2020, COVID-19 has been confirmed in 15,785,641 cases and 
caused 640,016 deaths globally.1 Although SARS-CoV-2 primarily affects the 
respiratory system, other organ systems such as cardiovascular, urinary and neuro-
logical systems are also involved.2 It is likely that COVID-19 survivors will have 
additional comorbidities requiring further support, including chronic pain.3 
Previous studies have suggested that chronic pain is not an uncommon complication 
following ICU discharge.4 Critical patients with COVID-19 are thought to be at 
high risk of developing chronic pain.5 However, the exact nature and mechanisms 
of COVID-19-related chronic pain remain largely unknown.
Postherpetic neuralgia is a chronic painful condition that can occur following 
herpes zoster, an extremely painful skin rash caused by the varicella zoster virus. 
Postherpetic neuralgia occurs most often in elderly people and in people with 
immunocompromise, who are also susceptible to COVID-19.6 Recently, there are 
case reports of herpes zoster in patients with both symptomatic and asymptomatic 
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SARS-CoV-2 infection.7,8 However, in these cases, no 
long-term follow up was performed and no postherpetic 
neuralgia was observed. Here, we report clinical features 
and treatments of herpes zoster and postherpetic neuralgia 
in an elderly patient with critical COVID-19. In addition, 
we review literatures about pathogenesis of COVID-19 
and herpes zoster, and the prevention and treatment of 
postherpetic neuralgia, in order to provide a targeted sug-
gestion for this kind of patient. This case report was 
approved by the Research and Ethics Committee of 
Tongji hospital at Tongji Medical College, Huazhong 
University of Science and Technology to publish the case 
details. Written informed consent has been provided by the 
patient to have the case details and any accompanying 
images published.
Case Presentation
A 70-year-old woman presented to the emergency depart-
ment with fever and dry cough of 3 days’ duration on 
January 17, 2020. Her medical history was noteworthy for 
type 2 diabetes and myasthenia gravis, for which she was 
taking acarbose (25 mg orally 3 times a day), pyridostig-
mine (120mg orally 3 times a day), prednisone (20mg 
orally once a day), and tacrolimus (2 mg orally once 
a day). The patient had a history of muscle weakness, 
with no respiratory failure, which was well controlled. In 
addition, the patient had a history of chickenpox but no 
previous documented episodes of herpes zoster. Chest CT 
scans showed multiple ground glass opacities and infiltra-
tion in both lungs. Blood examination showed a decreased 
leukocyte count of 3.4 x109/L and lymphocyte count of 0.6 
x 109/L (Table 1). The patient was diagnosed as 
a suspected case of COVID-19 and admitted to an infec-
tion isolation ward.
After admission, the diagnose of COVID-19 was con-
firmed based on positive results of real-time reverse tran-
scriptase–polymerase chain reaction (RT-PCR) tests for 
nucleic acid of SARS-CoV-2 (Novel Coronavirus PCR 
Fluorescence Diagnostic Kit, BioGerm Medical 
Biotechnology). She was treated with arbidol (0.2 
g orally every 8 h) and moxifloxacin (0.4 g orally 
every day). On January 27, 2020, she developed respira-
tory distress with breath rate > 30 per min and oxygen 
saturation < 93% at rest. Low-flow and then high-flow 
oxygen therapy via nasal cannula was started, but the 
symptoms did not improve. The patient was transferred 
to the intensive care unit and noninvasive mechanical 
ventilation was implemented. Nine days later, noninvasive 
mechanical ventilation was stopped and high-flow oxygen 
therapy via nasal cannula was continued. Her blood exam-
ination showed a repeatedly increased leukocyte and neu-
trophil count, indicating a potential bacterial infection. 
Thus, tacrolimus was stopped on February 13, 2020. Her 
clinical condition improved gradually. The patient was 
transferred to a general ward and oxygen therapy was 
stopped on February 23, 2020, and tacrolimus was 
restarted on March 3, 2020.
On March 5, 2020, there were clusters of small red 
papules occurring on her right side of the waist accompa-
nied by spontaneous sharp pain (rated as 8–9 on an 11- 
point numeric rating scale (NRS, 0–10), and a clinical 
diagnosis of herpes zoster was made. The patient received 
antiviral treatment with intravenous acyclovir (250 mg 3 
times a day), and prednisone (20mg orally once a day) was 
restarted. Meantime, infrared therapy were applied for 
promoting rash absorption, and pregabalin (75 mg orally 
twice a day) and ibuprofen was used for analgesia. 
A follow-up RT-PCR test for nucleic acid of SARS-CoV 
-2 was performed and the results were positive. On 
March 7, 2020 (day 3 of herpes zoster), most papules 
were replaced with clear vesicles and the pain was slightly 
relieved. On March 20, 2020 (day 16 of herpes zoster), the 
clear vesicles had become cloudy and some eventually 
crusted. Intravenous acyclovir was replaced with oral acy-
clovir (400 mg 5 times a day) and discontinued 7 days 
later. On March 25, 2020 (day 21 of herpes zoster), her 
skin lesions resolved (Figure 1). However, she continued 
to have persistent pain in the right 10 to 12 lumbar derma-
tomes. She experienced constant burning pain (NRS 5), 
intermittent electric shocks (NRS 7, >20 times a day, 
a 5-minute duration each). The dosage of pregabalin was 
increased to 150 mg orally twice a day. The constant pain 
decreased to 3/10 within 2 weeks. The intensity of inter-
mittent pain also decreased to 5/10 (3 times a day, 
a 3-minute duration each). On April 23, 2020, the patient 
was discharged to an isolation centre for 14 days of quar-
antine after recovery from COVID-19. On July 6, 2020 (4 
months after the onset of rash), the patient received 
a follow-up telephone call and reported that she still had 
intermittent pain in the right 10 to 12 lumbar dermatomes 
(NRS 3, 1–2 times per day, seconds for each episode).
Discussion
Postherpetic neuralgia is one of the most common causes of 
neuropathic pain, which affects up to a third of patients with 
herpes zoster.9 It is reported that herpes zoster cases 
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substantially increase during COVID-19 pandemic.8 
Because of limited knowledge about pathogenesis of SARS- 
CoV-2 infection, it is challenging to treat acute herpes zoster 
and prevent postherpetic neuralgia in COVID-19 patients. 
Here, we report the clinical features, treatment and prognosis 
of herpes zoster in an elderly patient with critical COVID- 
19, indicating the importance of early antiviral therapy.
Herpes zoster is caused by reactivation of latent var-
icella zoster virus. A decline in cell-mediated immune 
response is thought to play an important role in the patho-
genesis of herpes zoster.10 Decreased cell-mediated 
immune responses can be induced by advancing age, med-
ical treatments or immunosuppressive illnesses.11 In 
COVID-19 patients, SARS-CoV-2 infection may decrease 
primarily T lymphocytes, especially CD4+ and CD8+ 
T cells.12 In addition, the current patient had a history of 
myasthenia gravis and had been receiving tacrolimus ther-
apy. Myasthenia gravis is the most common humoral and 
cellular immune-mediated neuromuscular disorder. 
Dysregulation of regulatory T cells and elevated levels of 
pre-inflammatory cytokines such as IL-6 have been noted 
in myasthenia gravis patients.13 Tacrolimus, a calcineurin 
Table 1 Clinical Laboratory Results of the Patient
Day of illness Admission ICU Herpes zoster Discharge
D4 D14 D23 D29 D41 D52 D55 D59 D64 D74 D99
Measure Reference 
range
1/17 1/27 2/5 2/11 2/23 3/5 3/8 3/12 3/17 3/27 4/23
hs-CRP (mg/L) (<1) <1 67.6 248 1.3 1.8 0.4 58.9 5.5 1.3 0.3
WBC (×109/L) 3.50–9.50 3.4 13.8 13.12 12.62 14.77 5.37 9.66 6.1 8.86 7.99 6.05
NEUT (%) 40.0–75 73.3 92 86 80.6 83.4 61.3 75.7 52.9 61.7 52.1 48.7
NEUT (×109/L) 1.8–6.3 2.42 12.87 11.29 10.18 12.32 3.29 7.31 3.23 5.46 4.17 2.94
LYM (%) 20.0–50.0 18.1 5.3 9.7 10 10.4 28.9 19.6 42.5 35.9 35.8 43.8
LYM (×109/L) 1.10–3.20 0.6 0.74 1.27 1.26 1.54 1.55 1.89 2.59 3.18 2.86 2.65
MONO (%) 3.0–10 8.8 1.9 3.7 8.8 6 8.4 4.2 3.9 2.1 11.4 6.9
MONO (×109/L) 0.1–0.6 0.59 0.27 0.49 1.11 0.88 0.45 0.41 0.24 0.19 0.91 0.42
PLT (×109/L) 125–350 222 240 234 246 353 135 137 199 268 250 199
IL-1beta (pg/mL) <5.0 8.1 8.1 12.3 16 25.1
IL-2 receptor (U/mL) 223–710 368 368 305 318 241
IL- 6 (pg/mL) <7 6.31 6.31 2.53 <1.5 1.8
IL-8 (pg/mL) <62 19.7 19.7 21 12.5 10.6
IL-10 (pg/mL) <9.1 5.9 5.9 13 <5.0 7.5
TNF alpha <8.1 6.4 6.4 8.2 7.4 7.5








Th (%) 2–51 40.17 45.32
Th (cells/ul) 550–1440 1189 1115
Ts(%) 15–44 26.24 25.22
Ts (cells/ul) 320–1250 777 621
NK cell (%) 7–40 22.94 20.6
NK cell (cells/ul) 150–1100 679 507
Alanine 
aminotransferase (U/L)
≤33 8 5 13 19 18 16
Aspartate 
aminotransferase (U/L)
≤32 16 16 19 23 20 16
Creatinine (μmol/L) 45–84 54 54 50 41 47 45
Note: values in bold were above normal; values in italics were below normal. 
Abbreviations: ICU, intensive care unit; hs-CRP, high-sensitivity C-reactive protein; WBC, white blood cell; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte; PLT, 
platelet; IL, interleukin; TNF, tumor necrosis factor; Th, helper T cell; Ts, suppressor T cell; NK, nature killer.
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inhibitor, is one of the most effective agents in controlling 
the overall regulatory T cells, which can result in the 
inhibition of expression of IL-6. Earlier reports have 
described herpes zoster occurs before or after onset of 
COVID-19 symptoms with lymphopenia.7,8 However, in 
this patient, herpes zoster occurred in the recovery period 
of COVID-19 and the results of clinical laboratory mea-
surements were almost normal. This observation indicates 
the variety of COVID-19 and herpes zoster co-occurrence, 
and the complexity of the underling mechanisms.
Although herpes zoster is mostly self-limiting, antiviral 
therapy needs to be considered in patients with severe 
diseases such as COVID-19. Among antivirals for treat-
ment of herpes zoster licensed by the Food and Drug 
Administration (FDA), acyclovir is most commonly used. 
In the previous studies, acyclovir has been shown to 
reduce virus shedding, stop new lesion formation and 
hasten resolution of lesions.14,15 In the current report, the 
administration of acyclovir was started within 24 hours of 
rash onset and lasted for 21 days. It is recommended that 
antiviral treatment initiate within 72 hours of onset of the 
rash, and is usually given for 7 days.14 The principle of 
antiviral treatment in COVID-19 patients with herpes zos-
ter might be the same as in other patients with the condi-
tion. In patients with complications of herpes zoster, which 
might be more common in COVID-19 patients, the course 
of treatment needs to be extended. Considering the side 
effects of acyclovir such as hepatotoxicity and nephrotoxi-
city, liver and kidney function should be monitored reg-
ularly. Under certain circumstances such as 
contraindications of acyclovir, vitamin C and quercetin 
might be considered as alternative treatments, which 
have been proved to display immunomodulatory function 
and anti-viral effect.16 In addition, the patients with herpes 
zoster should be placed on contact precautions to avoid 
varicella zoster virus transmission to susceptible persons 
such as other COVID-19 patients.
Pain management is one of the cornerstones of treat-
ment of both acute herpes zoster and postherpetic neural-
gia. For mild to moderate pain, analgesics such as 
paracetamol and nonsteroidal anti-inflammatory drugs 
(NSAIDs) are appropriate. For severe pain, opioid analge-
sics such as oxycodone or morphine are options.15 In the 
first line treatment of postherpetic neuralgia, tricyclic 
Figure 1 Herpes zoster in a right-sided T10-12 dermatomal distribution. The vesicular crusts has fallen off leaving temporary pigmentation.
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antidepressants (like nortriptyline or amitriptyline), antic-
onvulsant (like gabapentin or pregabalin) and topically 
administered lidocaine may be used.17 Because the patient 
in the current report has a history of myasthenia gravis, 
drugs affecting the neuromuscular junction like anticon-
vulsants need to be used with caution. Although one antic-
onvulsant gabapentin has been widely reported to induce 
an exacerbation of myasthenic symptoms,18–20 another 
anticonvulsant pregabalin is well tolerant in the current 
case. Thus, in patients with COVID-19, the comorbidity 
and the side effects of analgesics should worth further 
attention to and be treated case by case. Where a single 
treatment alone is ineffective, combined modalities are 
recommended.
In summary, this case draws attention to postherpetic 
neuralgia in COVID-19 patients. For COVID-19 patients 
with herpes zoster, antiviral treatment should be started as 
early as possible and lastlonger than a typical course. The 
use of analgesics should be based on the dermatome 
involved, severity of pain and the comorbidities. Our 
report indicates that longer term outcomes of pain manage-
ment in COVID-19 patients should be monitored in future 
studies.
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